VCYT has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
VCYT has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Total Debt per Share is calculated as total debt divided by Shares Outstanding (EOP). Total debt is calculated as Long-Term Debt & Capital Lease Obligation plus Short-Term Debt & Capital Lease Obligation. Veracyte's Total Debt Per Share for the quarter that ended in Jun. 2024 was $0.27.
The historical data trend for Veracyte's Total Debt per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Veracyte Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
Total Debt per Share | Get a 7-Day Free Trial | 0.27 | 0.21 | 0.27 | 0.21 | 0.17 |
Veracyte Quarterly Data | ||||||||||||||||||||
Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | |
Total Debt per Share | Get a 7-Day Free Trial | 0.21 | 0.19 | 0.17 | 0.18 | 0.27 |
Veracyte's Total Debt Per Share for the fiscal year that ended in Dec. 2023 is calculated as:
Total Debt Per Share | = | (Long-Term Debt & Capital Lease Obligation | + | Short-Term Debt & Capital Lease Obligation) | / | Shares Outstanding (EOP) |
= | (7.5 | + | 5.1) | / | 73.3 | |
= | 0.17 |
Veracyte's Total Debt Per Share for the quarter that ended in Jun. 2024 is calculated as:
Total Debt Per Share | = | (Long-Term Debt & Capital Lease Obligation | + | Short-Term Debt & Capital Lease Obligation) | / | Shares Outstanding (EOP) |
= | (13.6 | + | 7.2) | / | 76.7 | |
= | 0.27 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thank you for viewing the detailed overview of Veracyte's Total Debt per Share provided by GuruFocus.com. Please click on the following links to see related term pages.
Phillip G. Febbo | officer: Chief Scientific & Med Officer | C/O GENOMIC HEALTH, INC., 301 PENOBSCOT DRIVE, REDWOOD CITY CA 94063 |
John Leite | officer: Chief Commercial Officer-CLIA | 6000 SHORELINE COURT, SUITE 300, SOUTH SAN FRANCISCO CA 94080 |
Evan/ Fa Jones | director | C/O OPGEN, INC., 708 QUINCE ORCHARD ROAD, SUITE 205, GAITHERSBURG MD 20878 |
John L Bishop | director | |
Muna Bhanji | director | C/O CYTOKINETICS, INCORPORATED, 280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080 |
Bonnie H Anderson | director, officer: President & CEO | 6000 SHORELINE COURT, SUITE 300, SOUTH SAN FRANCISCO CA 94080 |
Karin Eastham | director | C/O BURNHAM INSTITUTE FOR MEDICAL RESEAR, 10901 N. TORREY PINES ROAD, LA JOLLA CA 92037 |
Giulia C Kennedy | officer: Chief Scientific & Med Officer | 338 MAIN STREET #26E, SAN FRANCISCO CA 94105 |
Eliav Barr | director | C/O VERACYTE, INC., 6000 SHORELINE COURT, SUITE 300, SOUTH SAN FRANCISCO CA 94080 |
Jens Holstein | director | C/O VERACYTE, INC., 6000 SHORELINE COURT, SUITE 300, SOUTH SAN FRANCISCO CA 94080 |
Marc Stapley | officer: Chief Executive Officer | 9885 TOWNE CENTRE DRIVE, SAN DIEGO CA 92121 |
Kevin K Gordon | director | 155 S LIMERICK RD, LIMERICK PA 19468 |
Jonathan Wygant | officer: VP, Chief Accounting Officer | 3750 TORREY VIEW COURT, SAN DIEGO X1 92130 |
Annie Mcguire | officer: SVP, General Counsel | C/O VERACYTE, INC., 6000 SHORELINE COURT, SUITE 300, SOUTH SAN FRANCISCO CA 94080 |
Rebecca Chambers | officer: Chief Financial Officer | 3052 ORCHARD DR., SAN JOSE CA 95134 |
From GuruFocus
By Business Wire • 09-28-2023
By Business Wire Business Wire • 05-03-2023
By Business Wire • 08-29-2023
By Business Wire Business Wire • 05-23-2023
By Business Wire • 09-21-2023
By Business Wire • 10-12-2023
By Business Wire Business Wire • 05-04-2023
By Business Wire • 09-28-2023
By Business Wire • 10-04-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.